nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

01.12.2019 | editorial

Optimizing care for geriatric cancer patients: the greatest challenge in medical oncology?

verfasst von: Rupert Bartsch

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Excerpt

Fundamental progress has been achieved in the treatment of solid cancers over the last two decades and patients’ long-term outcome has improved accordingly. With monoclonal antibodies, small-molecule tyrosine kinase inhibitors and more recently, immune checkpoint modulators, a plethora of highly active novel drugs has become available. But are truly all patients benefitting from these successes? In an elderly population of breast cancer patients, the HER2-positive subtype was still associated with the worst prognosis as shown in a recent publication [1] despite the excellent survival results achieved within clinical trials [2]. …

Vorheriger Artikel Amazing advances in the field of uro-oncology

Nächster Artikel Prevalence of comorbidity in cancer patients scheduled for systemic anticancer treatment in Austria

Bergen ES, Tichy C, Berghoff AS, et al. Prognostic impact of breast cancer subtypes in elderly patients. Breast Cancer Res Treat. 2016;157(1):91–9.CrossRef

Swain SM, Kim SB, Cortés J, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013;14(6):461–71.CrossRef

Zeber JE, Copeland LA, Hosek BJ, Karnad AB, Lawrence VA, Sanchez-Reilly SE. Cancer rates, medical comorbidities, and treatment modalities in the oldest patients. Crit Rev Oncol Hematol. 2008;67(3):237–342.CrossRef

Balic M, Hilbe W, Gusel S, et al. Prevalence of comorbidity in cancer patients scheduled for systemic anticancer treatment in Austria. A cross-sectional multicenter observational study. memo. 2019;12(4). https://doi.org/10.1007/s12254-019-00542-7.CrossRef

Yancik R, Wesley MN, Ries LA, Havlik RJ, Edwards BK, Yates JW. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA. 2001;285(7):885–92.CrossRef

Pallis AG, Fortpied C, Wedding U, et al. EORTC elderly task force position paper: approach to the older cancer patient. Eur J Cancer. 2010;46:1502–13.CrossRef

Titel: Optimizing care for geriatric cancer patients: the greatest challenge in medical oncology?
verfasst von: Rupert Bartsch
Publikationsdatum: 01.12.2019
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 4/2019
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-019-00535-6

Springer Medizin Österreich

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2019

Management of nonmetastatic muscle invasive bladder cancer in the elderly

Giant leiomyoma of the renal capsule: CT and MR imaging features with pathologic correlations

ASCO 2019—Personal highlights on adjuvant breast cancer: (neo-)adjuvant therapy of HER2-negative HR-positive BC

Advanced/metastatic urothelial carcinoma of the bladder and upper urinary tract

Adjuvant breast cancer: (neo)adjuvant therapy for HER2-positive breast cancer

Prevalence of comorbidity in cancer patients scheduled for systemic anticancer treatment in Austria